Premium
Effect of fenretinide on plasma IGF‐I and IGFBP‐3 in early breast cancer patients
Author(s) -
Torrisi Rosalba,
Parodi Stefano,
Fontana Vincenzo,
Pensa Floriana,
Casella Claudia,
Barreca Antonina,
De Palo Giuseppe,
Costa Alberto,
Decensi Andrea
Publication year - 1998
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19980610)76:6<787::aid-ijc3>3.0.co;2-u
Subject(s) - fenretinide , retinoid , endocrinology , medicine , receptor , breast cancer , bioavailability , mammary gland , cancer , biology , pharmacology , biochemistry , retinoic acid , gene
Growing evidence substantiates the role of the insulin‐like growth factor I (IGF‐I) system in breast tumorigenesis. Retinoids have been shown to affect the IGF system in several experimental models. We extended our previous data on plasma IGF‐I modulation by the synthetic retinoid fenretinide (4‐HPR) and investigated the effect of the retinoid on plasma IGF binding protein (BP)‐3, the major protein binding IGFs. IGF‐I and IGFBP‐3 were measured on plasma samples obtained at randomization and after an interval of approximately 1 year, from 39 and 33 stage I breast cancer patients assigned to receive 4‐HPR, and from 39 and 34 untreated controls, respectively. There was a significant decrease in plasma IGF‐I after 4‐HPR administration, whereas no significant change was observed in controls. The effect of 4‐HPR on IGF‐I levels was modified by menopausal status, inasmuch as the decrease in IGF‐I was particularly pronounced in pre‐menopausal women, whereas the reverse was observed in untreated controls. By contrast, treatment induced an increase of IGFBP‐3 with respect to controls. As a result of this dual effect, the bioavailability of IGF‐I for interaction with receptors at target levels further decreased in pre‐menopausal 4‐HPR‐treated patients compared with controls, suggesting that retinoid administration may result in lower concentrations of biologically active IGF‐I. Our findings may have important implications for the clinical preventive activity of this retinoid. Int. J. Cancer 76:787–790, 1998.© 1998 Wiley‐Liss, Inc.